PH12018500859A1 - Crystalline form of 2-(2,6-dichlorophenyl)-1-[(1s,3r)-3-(hydroxymethyl)-5-(3-hydroxy-3-methylbutyl)-1-methyl-3,4-dihydroisoquinolin-2(1h)-yl]ethanone for the treatment of parkinson`s disease - Google Patents

Crystalline form of 2-(2,6-dichlorophenyl)-1-[(1s,3r)-3-(hydroxymethyl)-5-(3-hydroxy-3-methylbutyl)-1-methyl-3,4-dihydroisoquinolin-2(1h)-yl]ethanone for the treatment of parkinson`s disease

Info

Publication number
PH12018500859A1
PH12018500859A1 PH12018500859A PH12018500859A PH12018500859A1 PH 12018500859 A1 PH12018500859 A1 PH 12018500859A1 PH 12018500859 A PH12018500859 A PH 12018500859A PH 12018500859 A PH12018500859 A PH 12018500859A PH 12018500859 A1 PH12018500859 A1 PH 12018500859A1
Authority
PH
Philippines
Prior art keywords
dihydroisoquinolin
ethanone
methylbutyl
dichlorophenyl
hydroxymethyl
Prior art date
Application number
PH12018500859A
Inventor
Gregory Alan Stephenson
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of PH12018500859A1 publication Critical patent/PH12018500859A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
    • C07D217/14—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
    • C07D217/16—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals substituted by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention provides a crystalline form of 2-(2,6-dichlorophenyl)-1-[(1S,3R)-3-(hydroxymethyl)-5-(3-hydroxy-3-methylbutyl)-1-methyl-3,4-dihydroisoquinolin-2(1H)-yl]ethanone, and pharmaceutical compositions thereof. The invention further provides methods of using a crystalline form of 2-(2,6-dichlorophenyl)-1-[(1S,3R)-3-(hydroxymethyl)-5-(3-hydroxy-3-methylbutyl)-1-methyl-3,4-dihydroisoquinolin-2(1H)-yl]ethanone to treat cognitive impairment associated with Parkinson's disease or schizophrenia.
PH12018500859A 2015-10-23 2018-04-20 Crystalline form of 2-(2,6-dichlorophenyl)-1-[(1s,3r)-3-(hydroxymethyl)-5-(3-hydroxy-3-methylbutyl)-1-methyl-3,4-dihydroisoquinolin-2(1h)-yl]ethanone for the treatment of parkinson`s disease PH12018500859A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562245391P 2015-10-23 2015-10-23
PCT/US2016/057447 WO2017070068A1 (en) 2015-10-23 2016-10-18 Crystalline form of 2-(2,6-dichlorophenyl)-1-[(1s,3r)-3-(hydroxymethyl)-5-(3-hydroxy-3-methylbutyl)-1-methyl-3,4-dihydroisoquinolin-2(1h)-yl]ethanone for the treatment of parkinson's disease

Publications (1)

Publication Number Publication Date
PH12018500859A1 true PH12018500859A1 (en) 2018-10-29

Family

ID=57233858

Family Applications (1)

Application Number Title Priority Date Filing Date
PH12018500859A PH12018500859A1 (en) 2015-10-23 2018-04-20 Crystalline form of 2-(2,6-dichlorophenyl)-1-[(1s,3r)-3-(hydroxymethyl)-5-(3-hydroxy-3-methylbutyl)-1-methyl-3,4-dihydroisoquinolin-2(1h)-yl]ethanone for the treatment of parkinson`s disease

Country Status (13)

Country Link
CN (1) CN108137506A (en)
AR (1) AR106332A1 (en)
AU (1) AU2016341115A1 (en)
CA (1) CA2999332A1 (en)
DO (1) DOP2018000103A (en)
EA (1) EA201890525A1 (en)
EC (1) ECSP18030976A (en)
IL (1) IL257872A (en)
MX (1) MX2018004794A (en)
PE (1) PE20181296A1 (en)
PH (1) PH12018500859A1 (en)
TW (1) TW201725199A (en)
WO (1) WO2017070068A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI725408B (en) * 2018-04-20 2021-04-21 美商美國禮來大藥廠 Dopamine d1 receptor positive allosteric modulators
JP2022514659A (en) * 2018-12-18 2022-02-14 イーライ リリー アンド カンパニー Dose regimen for the use of LY3152207 in the treatment of dopaminergic CNS disorders
TWI825323B (en) * 2019-06-18 2023-12-11 美商美國禮來大藥廠 Processes and intermediates for the preparation of 2-(2,6-dichlorophenyl)-1-[(1s,3r)-3-(hydroxymethyl)-5-(3-hydroxy-3-methylbutyl)-1-methyl-3,4-dihydroisoquinolin-2(1h)-yl]ethanone
WO2022192231A1 (en) 2021-03-08 2022-09-15 Eli Lilly And Company Use of mevidalen and other d1 positive allosteric modulators in the treatment of hallucinations and dementia-related psychosis
EP4304577A1 (en) 2021-03-09 2024-01-17 Eli Lilly And Co. Use of mevidalen and other d1 positive allosteric modulators for slowing of parkinson's disease progression
CN113264926A (en) * 2021-05-31 2021-08-17 东北林业大学 Co-crystal of vitexin and reserpine and preparation method thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5236934A (en) * 1992-08-26 1993-08-17 E. I. Du Pont De Nemours And Company 1,2,3,4-tetrahydroisoquinolines useful in the treatment of CNS disorders
BRPI0808525A2 (en) * 2007-03-01 2014-08-19 Janssen Pharmaceutica Nv TETRAHYDROISOQUINOLINE COMPOUNDS AS HISTAMINE H3 RECEPTOR MODULATORS
US20120252853A1 (en) * 2011-04-01 2012-10-04 H. Lundbeck A/S Positive allosteric modulators of nicotinic acetylcholine receptor
JO3316B1 (en) * 2013-05-30 2019-03-13 Lilly Co Eli 3,4-dihydroisoquinolin-2(1h)-yl compounds

Also Published As

Publication number Publication date
TW201725199A (en) 2017-07-16
AR106332A1 (en) 2018-01-03
CN108137506A (en) 2018-06-08
WO2017070068A1 (en) 2017-04-27
DOP2018000103A (en) 2018-10-31
CA2999332A1 (en) 2017-04-27
AU2016341115A1 (en) 2018-04-12
ECSP18030976A (en) 2018-05-31
MX2018004794A (en) 2018-06-19
IL257872A (en) 2018-06-03
EA201890525A1 (en) 2018-09-28
PE20181296A1 (en) 2018-08-07

Similar Documents

Publication Publication Date Title
PH12018500859A1 (en) Crystalline form of 2-(2,6-dichlorophenyl)-1-[(1s,3r)-3-(hydroxymethyl)-5-(3-hydroxy-3-methylbutyl)-1-methyl-3,4-dihydroisoquinolin-2(1h)-yl]ethanone for the treatment of parkinson`s disease
EP3638315A4 (en) Aadc polynucleotides for the treatment of parkinson's disease
MX2021000071A (en) Use of pridopidine to improve cognitive function and for treating alzheimer's disease.
PE20152032A1 (en) 3,4-DIHYDROISOQUINOLIN-2 (1H) -IL COMPOUNDS
IL269599B1 (en) 11,13-modified saxitoxins for the treatment of pain
WO2015132799A3 (en) Heterocyclic compounds
EP3778605A3 (en) Lrrk2 inhibitors and methods of making and using the same
IL285782A (en) Compounds, compositions, and methods for the treatment of disease
WO2015001504A3 (en) Antibody formulations and methods
WO2015171610A3 (en) Tetrahydroquinoline sulfonamide and related compounds for use as agonists of rory and the treatment of disease
MA44759B1 (en) POLYMORPH FORM OF N-(6-(2-HYDROXYPROPAN-2-YL)-2-[2-(METHYLSULFONYL)ETHYL]-2H-INDAZOL-5-YL)-6-(TRIFLUOROMETHYL)PYRIDINE-2-CARBOXAMIDE
EP3562514A4 (en) Gene therapy for treating wilson's disease
MX2017009417A (en) Solid forms of 2-(5-(3-fluorophenyl)-3-hydroxypicolinamido)acetic acid, compositions, and uses thereof.
WO2018067520A3 (en) Therapeutic agents and methods:
NZ746468A (en) Methods of treating ocular conditions
FI3609886T3 (en) Benzoazepine analogs as inhibiting agents for bruton's tyrosine kinase
EA201691567A1 (en) METHODS OF TREATING PULMONARY INJURIES TO THE BRAIN
MX2018005987A (en) Heterocyclic compounds for the treatment of disease.
TN2016000447A1 (en) Heteroaromatic compounds and their use as dopamine d1 ligands.
IL270927B (en) 5,6-fused-bicyclic compounds and compositions for the treatment of parasitic diseases
EP3730144A4 (en) Agent for treatment of nervous system disease
MA39450A1 (en) Pharmaceutically acceptable salts of pirlindole enantiomers for use in medicine
EP3556366A4 (en) Use of carbamate compounds for prevention, alleviation or treatment of bipolar disorder
MA39448A1 (en) (R) -pirlindole and its pharmaceutically acceptable salts for medical use
WO2017103892A3 (en) Composition for treating and preventing neurological diseases, neuroinflammation, and alzheimer's disease